Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-02-16 3:01 pm Sale |
2020-12-31 | 13G | ChemoCentryx, Inc. CCXI |
Cormorant Asset Management LP | 1,200,000 1.700% |
-2,186,208 (-64.56%) |
Filing History |
| 2021-02-16 3:00 pm Sale |
2020-12-31 | 13G | Revolution Medicines, Inc. RVMD |
Cormorant Asset Management LP | 2,495,066 3.800% |
-750,111 (-23.11%) |
Filing History |
| 2021-01-19 4:18 pm Purchase |
2021-01-07 | 13G | MIRAGEN THERAPEUTICS INC MGEN |
Cormorant Asset Management LP | 459,144 9.990% |
459,144 (New Position) |
Filing History |
| 2021-01-04 4:01 pm Purchase |
2020-12-22 | 13G | NOVUS THERAPEUTICS INC NVUS |
Cormorant Asset Management LP | 1,415,500 9.890% |
1,415,500 (New Position) |
Filing History |
| 2020-12-28 4:01 pm Purchase |
2020-12-18 | 13G | BioAtla, Inc. BCAB |
Cormorant Asset Management LP | 2,292,060 7.120% |
2,292,060 (New Position) |
Filing History |
| 2020-11-23 4:59 pm Purchase |
2020-11-23 | 13G | Olema Pharmaceuticals, Inc. OLMA |
Cormorant Asset Management LP | 3,270,544 8.140% |
3,270,544 (New Position) |
Filing History |
| 2020-11-13 4:01 pm Purchase |
2020-11-03 | 13G | Atea Pharmaceuticals, Inc. AVIR |
Cormorant Asset Management LP | 6,886,355 8.340% |
6,886,355 (New Position) |
Filing History |
| 2020-11-12 4:22 pm Purchase |
2020-11-02 | 13G | Galecto, Inc. GLTO |
Cormorant Asset Management LP | 91,249 9.280% |
91,249 (New Position) |
Filing History |
| 2020-10-30 4:00 pm Purchase |
2020-10-20 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
Cormorant Asset Management LP | 1,964,268 9.780% |
1,964,268 (New Position) |
Filing History |
| 2020-10-16 4:00 pm Purchase |
2020-10-06 | 13G | C4 Therapeutics, Inc. CCCC |
Cormorant Asset Management LP | 2,490,068 5.790% |
2,490,068 (New Position) |
Filing History |
| 2020-07-20 4:03 pm Purchase |
2020-07-10 | 13G | Otonomy, Inc. OTIC |
Cormorant Asset Management LP | 2,500,000 5.200% |
2,500,000 (New Position) |
Filing |
| 2020-07-06 4:01 pm Purchase |
2020-06-23 | 13G | Forma Therapeutics Holdings, Inc. FMTX |
Cormorant Asset Management LP | 3,379,370 8.760% |
3,379,370 (New Position) |
Filing History |
| 2020-06-29 5:22 pm Unchanged |
2020-06-17 | 13G | AVEO Pharmaceuticals, Inc. AVEO |
Cormorant Asset Management LP | 1,350,000 5.230% |
0 (Unchanged) |
Filing History |
| 2020-06-29 5:22 pm Purchase |
2020-06-17 | 13G | AVEO Pharmaceuticals, Inc. AVEO |
Cormorant Asset Management LP | 1,350,000 5.230% |
1,350,000 (New Position) |
Filing History |
| 2020-06-26 4:17 pm Purchase |
2020-06-16 | 13G | Avidity Biosciences, Inc. RNA |
Cormorant Asset Management LP | 2,514,545 6.700% |
2,514,545 (New Position) |
Filing History |